All Stories

  1. The role of gut microbiota in the pathogenesis of primary biliary cholangitis: an immunological perspective
  2. Annurca Apple Extract and Colorectal Cancer Prevention: Preliminary In Silico Evaluation of Chlorogenic Acid
  3. Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma
  4. Metabolic Signatures of Breast Cancer Subtypes and the Metabolic Impact of Chemotherapy
  5. Gender, Age, Alpha-fetoprotein, and Des-gamma-carboxyprothrombin Score as a Novel Approach to Early Detection of Hepatocellular Carcinoma: A Narrative Review
  6. Guideline comparison for fatty liver disease: European (EASL-EASD-EASO) and Asian (APASL) perspectives
  7. Impact of Radiomic and Artificial Intelligence on Colorectal Cancer: A Narrative Review
  8. Gut Microbiota Changes in Metabolic Dysfunction-Associated Steatohepatitis and Inflammatory Bowel Disease: Common Pathogenic Features
  9. Metabolic Dysfunction-Associated Steatotic Liver Disease in a Patient with Phelan–McDermid Syndrome
  10. Impact of Endoscopic Band Ligation on Gastric Complications Associated with Portal Hypertension
  11. Whey Proteins and Metabolic Dysfunction-Associated Steatotic Liver Disease Features: Evolving the Current Knowledge and Future Trends
  12. Comment on Rotaru et al. Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis. Life 2025, 15, 288
  13. Energy Requirements in the Post-ICU Period: An Exploratory Multicenter Observational Study
  14. Combined Model for the Diagnosis of Hepatocellular Carcinoma: A Pilot Study Comparing the Liver to Spleen Volume Ratio and Liver Vein to Cava Attenuation
  15. Impact of Endoscopic Band Ligation on Gastric Complications Associated with Portal Hypertension
  16. Combined Model as a Predictor of Hepatocellular Carcinoma: A Pilot Study Comparing Liver Segmental Volume Ratio and Liver Vein to Cava Attenuation
  17. Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia
  18. Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases
  19. Editorial Board Members’ Collection Series: Gastrointestinal and Hepatic Diseases
  20. The levels of inflammatory, angiogenic, and stress biomarkers in plasma of donors depending on anti-SARS-CoV-2 IgG titers
  21. Preventive and Therapeutic Effects of Baicalein, Galangin, and Isorhamnetin in Chronic Liver Diseases: A Narrative Review
  22. The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels
  23. Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
  24. Gut microbiota: the pathogenetic bridge between inflammatory bowel disease and metabolic-associated steatotic liver disease
  25. Impact of Protein and Nutritional Support on the Muscular Status of Critically Ill Patients: A Pilot, Perspective, and Exploratory Study
  26. Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
  27. Use of Non-Invasive Biomarkers and Clinical Scores to Predict the Complications of Liver Cirrhosis: A Bicentric Experience
  28. The anticancer activity of quercetin, luteolin, myricetin, and kaempferol in the development of hepatocellular carcinoma: a narrative review
  29. Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols
  30. Unraveling Pneumomediastinum in COVID-19 Patients: Insights from a High-Volume-Center Case–Control Study
  31. Sarcopenia and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
  32. Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study
  33. The Diagnosis of Wilkie’s Syndrome Associated with Nutcracker Syndrome: A Case Report and Literature Review
  34. Clostridioides difficile Infection: Use of Inflammatory Biomarkers and Hemogram-Derived Ratios to Predict Mortality Risk in Hospitalized Patients
  35. Sarcopenia and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
  36. Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma
  37. Diagnosis of Wilkie’s Syndrome Associated with Nutcracker Syndrome: A Case Report and Literature Review
  38. International medical educational space in the context of digital civilization
  39. Impact of diet and gut microbiota changes in the development of hepatocellular carcinoma
  40. Onion Polyphenols as Multi-Target-Directed Ligands in MASLD: A Preliminary Molecular Docking Study
  41. Change in Diagnosis of Helicobacter pylori Infection in the Treatment-Failure Era
  42. The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation
  43. The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
  44. The COVID-19 Pandemic Is Over, but the Virus Still Lingers
  45. The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation
  46. The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
  47. Onion Polyphenols as Multi-Target-Directed Ligands in MASLD – a Preliminary Molecular Docking Study
  48. Post-Coronavirus Disease 2019 Pandemic Antimicrobial Resistance
  49. Comment on Meneghini et al. The Impact of Nutritional Therapy in the Management of Overweight/Obese PCOS Patient Candidates for IVF. Nutrients 2023, 15, 4444
  50. Decoding MASLD’s Pathophysiology
  51. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study
  52. Effects of Origanum majorana on Breast Cancer Cells: An Alternative to Chemotherapy?
  53. Liver Damage and Impaired Coagulation in COVID-19 Patients: A Case Series
  54. Impact of Immuno-Nutrition on the Nutritional Status, Inflammatory Response and Clinical Outcome of Clinic-Admitted Mild-Intensity-COVID-19 Patients: A Pilot, Perspective-Concluding Study
  55. Gut Microbiota and Critically Ill Patients: Immunity and Its Modulation via Probiotics and Immunonutrition
  56. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
  57. Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687
  58. Gut Microbiota and Liver Transplantation: Immune Mechanisms behind the Rejection
  59. Diagnosis of Liver Fibrosis Using Artificial Intelligence: A Systematic Review
  60. Race: How the Post-Genomic Era Has Unmasked a Misconception Promoted by Healthcare
  61. Case Report: A Migrating Stitch in a Crohn’s Disease Patient
  62. Liver Damage and COVID-19: At Least a “Two-Hit” Story in Systematic Review
  63. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
  64. Effect of Immuno-Nutrition on Malnutrition, Inflammatory Response and Clinical Course of Semi-Critically Ill COVID-19 Patients: A Pilot Perspective Study
  65. The Use of Peppermint Oil in Gastroenterology
  66. COVID-19: Where We Are and Where We Are Going
  67. Decompressive Craniectomy in Severe Traumatic Brain Injury: The Intensivist’s Point of View
  68. Recent Advances and Future Challenges in the Field of Digestive Diseases
  69. Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay
  70. The Role of Autopsy and Post-Mortem Investigations in Falling Traumas in the Hospital Environment
  71. Nutritional Support in Acute Liver Failure
  72. Fecal Microbiota Transplantation in NAFLD Treatment
  73. Alagille Syndrome and Its Clinical and Laboratory Features: A Case Report
  74. How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care
  75. Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update
  76. The Legacy of Renato Dulbecco in the Post-Genomic Era
  77. Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
  78. Predicting the Spread of SARS-CoV-2 in Italian Regions: The Calabria Case Study, February 2020–March 2022
  79. Mediterranean Diet: The Beneficial Effects of Lycopene in Non-Alcoholic Fatty Liver Disease
  80. The Gut Microbiota Changes in Obese People: A New Perspective for the Modern Medicine
  81. Biological Mechanisms behind Wischnewsky Spots Finding on Gastric Mucosa: Autopsy Cases and Literature Review
  82. Phenotypic Variability in Phelan–McDermid Syndrome and Its Putative Link to Environmental Factors
  83. Effect of Whey Proteins on Malnutrition and Extubating Time of Critically Ill COVID-19 Patients
  84. Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
  85. From Pre- and Probiotics to Post-Biotics: A Narrative Review
  86. Изменения состава микробиоты кишечника, связанные с ожирением: новые результаты метагеномного анализа
  87. Probiotic Bacterial Application in Pediatric Critical Illness as Coadjuvants of Therapy
  88. Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care
  89. Intravenous Magnesium – Lidocaine - Ketorolac Cocktail for Postoperative Opioid Resistant Pain: A Case Series of Novel Rescue Therapy
  90. Management of Leaks Following Laparoscopic Sleeve Gastrectomy Using Specifically Designed Large Covered Metal Stents
  91. SARS-CoV-2 Spread Dynamics in Italy: The Calabria Experience
  92. Lock, Stock and Barrel: Role of Renin-Angiotensin-Aldosterone System in Coronavirus Disease 2019
  93. Nutritional Status and the Critically Ill Patient: Gut Microbiota and Immuno-Nutrition in I.C.U. at the Time of SARS-COV 2 Pandemic
  94. Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives
  95. New Strategies for Clinical Trials in Autism Spectrum Disorder
  96. Anxiety and Gastrointestinal Symptoms Related to COVID-19 during Italian Lockdown
  97. Resveratrol and other Stilbenes: Effects on Dysregulated Gene Expression in Cancers and Novel Delivery Systems
  98. Metabolic Benefits of Probiotic Combination with Absorbent Smectite in type 2 Diabetes Patients a Randomised Controlled Trial
  99. Preface
  100. The Plastic and Functional Changes in Hippocampal Neurons During Pregnancy, Delivery and Postpartum are Reversed by Offspring Deprivation
  101. Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease
  102. Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection
  103. Analysis of Nonsteroidal Anti-inflammatory Drugs by using Microfluidic Techniques: A Review
  104. Anti-Toxoplasmic Immunoglobulin G Quantitation Correlates with Immunovirological Parameters of HIV-Infected Cameroonians
  105. Mid-Aortic Syndrome: A Rare Cause of Renovascular Hypertension in Childhood Treated Percutaneously with an Unusual Vascular Access
  106. Neonatal Hyperbilirubinemia: An Updated Appraisal of National Guidelines
  107. G-Protein Coupled Receptors Involved in the Resolution of Inflammation: Ligands and Therapeutic Perspectives
  108. Focus on Phytochemical and Pharmacological Profile of Prunus lycioides (=Amygdalus lycioides)
  109. Indications for Non-Invasive Ventilation in Respiratory Failure
  110. Management of Gastrointestinal Bleeding in Rendu-Osler Disease
  111. Liver Cirrhosis Complications Management at the Emergency Department
  112. Disk Battery Ingestion: A Simple User-Guide
  113. Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1
  114. A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding
  115. Management of Pleural Effusions in the Emergency Department
  116. Clinical Management of Infectious Diarrhea
  117. Honey Against Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. An Umbrella Review of Systematic Reviews and Meta- Analyses of the Literature
  118. An Approach to Diabetic Ketoacidosis in an Emergency Setting
  119. Bedside Cardiac Pocus in Emergency Setting: A Practice Review
  120. Gut Alterations in Septic Patients: A Biochemical Literature Review
  121. New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases
  122. The Role of Targeted HIV Screening in the Emergency Department: A Scoping Review
  123. Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?
  124. Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
  125. Fibrotic Strictures in Crohn’s Disease: Mechanisms and Predictive Factors
  126. COVID-19: a Great Mime or a Trigger Event of Autoimmune Manifestations?
  127. Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study
  128. Prevention of COVID-19 Infection in the Medical Population: Possible Help from Anosmia?
  129. Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship
  130. Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review
  131. Dealing with COVID-19: lessons learned from the Italian experience
  132. COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey
  133. Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic
  134. The role of the COVID-19 pandemic as a risk factor for suicide: What is its impact on the public mental health state today?
  135. The Deadly Quartet (Covid-19, old age, lung disease, and heart failure) explain why coronavirus-related mortality in northern Italy was so high
  136. Electrophysiological and Clinical Improvement in Non-Invasive Treatment of Carpal Tunnel Syndrome
  137. The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study
  138. Smart Nanocarriers for Targeted Cancer Therapy
  139. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
  140. Circadian rhythms of endothelial nitric oxide synthase and toll-like receptors 2 production in females with rheumatoid arthritis depending on NOS3 gene polymorphism
  141. Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)
  142. Barriers And Facilitators In Conducting Clinical Trials In Inflammatory Bowel Disease: A Monocentric Italian Survey
  143. Preface
  144. Gut Microbiota and Obesity: A Role for Probiotics
  145. High Flow Through Nasal Cannula in Stable and Exacerbated Chronic Obstructive Pulmonary Disease Patients
  146. The Skin in Celiac Disease Patients: The Other Side of the Coin
  147. Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease
  148. Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way
  149. Self-Prescribed Dietary Restrictions are Common in Inflammatory Bowel Disease Patients and Are Associated with Low Bone Mineralization
  150. A Hazelnut-Enriched Diet Modulates Oxidative Stress and Inflammation Gene Expression without Weight Gain
  151. Olive oil antioxidants and non-alcoholic fatty liver disease
  152. Lamium Plants—A Comprehensive Review on Health Benefits and Biological Activities
  153. Use of Complementary and Alternative Medicine by Patients with Irritable Bowel Syndrome According to the Roma IV Criteria: A Single-Center Italian Survey
  154. Effect of Chondroitin Sulfate on Blood Serum Cytokine Profile during Carrageenan-induced Edema and Monoiodoacetate-induced Osteoarthritis in Rats
  155. Preface
  156. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
  157. Rosmarinic Acid as Potential Anti-Inflammatory Agent
  158. A Systematic Review on Natural Antioxidant Properties of Resveratrol
  159. Milk thistle (Silybum marianum ): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases
  160. Basics in Endoscopic Ultrasound Part 2: EUS-guided Sampling and Therapeutic Applications
  161. Resistin levels in non-alcoholic fatty liver disease pathogenesis
  162. Serum Complement C3 and Type 2 Diabetes in Rheumatoid Arthritis: a Case-Control Study
  163. Basics in Endoscopic Ultrasound Part 1: Diagnostic Indications and Tissue Sampling
  164. The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence
  165. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study
  166. Gut microbiota changes and chronic hepatitis C virus infection
  167. Adiponectin serum level changes and its dynamic relationship with hepatitis C during viral clearance
  168. Polyphenols treatment in patients with nonalcoholic fatty liver disease
  169. The influence of phthalates and bisphenol A on the obesity development and glucose metabolism disorders
  170. Editorial (Thematic Issue: Alcoholic Liver Disease: From Bench to Bedside)
  171. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence
  172. Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship
  173. Estimation of in vivo and in vitro exposure to bisphenol A as food contaminant
  174. Meet Our Editorial Board Member:
  175. Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia
  176. The Role of Liver Biopsy to Assess Non-Alcoholic Fatty Liver Disease
  177. Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease
  178. Phytotherapy and NAFLD - from Goals and Challenges to Clinical Practice
  179. Non Alcoholic Fatty Liver: Epidemiology and Natural History
  180. non-alcoholic fatty liver disease
  181. Effects of Mediterranean diet supplemented with silybin–vitamin E–phospholipid complex in overweight patients with non-alcoholic fatty liver disease
  182. Non-alcoholic fatty liver disease and beneficial effects of dietary supplements
  183. Adiponectin serum level in chronic hepatitis C infection and therapeutic profile
  184. C677T gene polymorphism of MTHFR and metabolic syndrome: response to dietary intervention
  185. Enhanced Expression of Indoleamine 2,3-Dioxygenase inHelicobacter pylori-Infected Human Gastric Mucosa Modulates Th1/Th2 Pathway and Interleukin 17 Production
  186. Su1939 Enhanced Expression of Indoleamine 2,3-Dioxygenase (IDO) in Helicobacter pylori-Infected Human Gastric Mucosa Modulates TH1/Th2 Pathway and Interleukin (IL)-17 Production
  187. 1028 High Exposure, Spontaneous Clearance and Low Incidence of Active Helicobacter pylori Infection: The Sorbo San Basile Study
  188. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism
  189. Pharmacotherapy of acute alcoholic hepatitis in clinical practice
  190. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet
  191. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3
  192. Prevalence of Peripheral Artery Disease by Abnormal Ankle-Brachial Index in Atrial Fibrillation
  193. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori
  194. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?
  195. Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or consequence?
  196. Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center
  197. Dietary Intervention in Non-Alcoholic Fatty Liver Disease
  198. Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
  199. Hepatitis C virus genotypes in north eastern Algeria: A retrospective study
  200. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease
  201. Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin
  202. Helicobacter species and liver disease
  203. High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease
  204. Il danno epatico da farmaci
  205. Bone Mineralization in Celiac Disease
  206. No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease
  207. Adiponectin levels in nonalcoholic fatty liver disease
  208. Transient Elastography for Assessment of Non-Alcoholic Fatty Liver Disease
  209. Insulin resistance increases risk of carpal tunnel syndrome: a case-control study
  210. Chronic hepatitis C infection and insulin resistance: two best friends
  211. “. . . and Suddenly a Tree!”
  212. Role of silymarin to treat fibrosis development in non-alcoholic fatty liver disease
  213. Non-alcoholic fatty liver disease and pharmacological options
  214. Short-term Therapy with Celecoxib and Lansoprazole Modulates Th1/ Th2 Immune Response in Human Gastric Mucosa
  215. Milk thistle in liver diseases: past, present, future
  216. Metformin: A Therapeutic Option for Treating Nonalcoholic Fatty Liver Disease
  217. Brain hypoperfusion and neurological symptoms in celiac disease
  218. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study
  219. Nervous system in the gluten syndrome: A close relationship
  220. Celiac disease: from gluten to skin
  221. Behçet’s disease and celiac disease: a rare association or a possible link?
  222. Phytotherapeutic approach to alcohol dependence: New old way?
  223. Subclinical Neurological Abnormalities and Gluten-Free Diet
  224. Acute alcohol intoxication
  225. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
  226. State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting
  227. Subclinical Neurological Abnormalities in Patients With Celiac Disease: Are They Associated by Brain Hypoperfusion?
  228. Complementary therapies for treating alcoholism
  229. Elastography assessment in patients with chronic HCV infection
  230. Intestinal Malabsorption and Skin Diseases
  231. Affective and Psychiatric Disorders in Celiac Disease
  232. Probiotics: Which and When?
  233. Metabolic and Nutritional Features in Adult Celiac Patients
  234. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study
  235. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study
  236. Neuroendocrine and Psychological Assessment in a Guinness 10 Days Scuba Dive
  237. Analysis of the T1288R Mutation of the Wilson Disease ATP7B Gene in Four Generations of a Family: Possible Genotype-Phenotype Correlation with Hepatic Onset
  238. Celiac disease and skin: Psoriasis association
  239. Relationship Between Ghrelin Levels, Alcohol Craving, and Nutritional Status in Current Alcoholic Patients
  240. Marked Decrease of Serum Ca 125 Levels After Denver Shunt Placement in a Patient With Cirrhosis and Refractory Ascites
  241. Complementary medicine for alcohol dependence in Italian services: A mail questionnaire
  242. Primary renal angiosarcoma: A rare malignancy. A case report and review of the literature☆
  243. Genotype–phenotype correlation of the Wilson diseaseATP7B gene
  244. Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam
  245. A New Mutation of Wilson's Disease P-Type ATPase Gene in a Patient with Cirrhosis and Coombs-Positive Hemolytic Anemia
  246. Neurobiochemical and clinical aspects of craving in alcohol addiction: A review
  247. CELIAC DISEASE AND SKIN DISORDERS
  248. Psychological Support Counseling: A New Strategy to Increase Gluten-Free Diet Compliance in Celiac Patients
  249. Association between psoriasis and coeliac disease
  250. Suppression of Craving for ??-Hydroxybutyric Acid by Naltrexone Administration
  251. Gamma hydroxybutyrric acid (GHB) withdrawal does not occur at therapeutic dosage
  252. How Many Cravings? Pharmacological Aspects of Craving Treatment in Alcohol Addiction: A Review
  253. Neurologic Disorders in Patients With Celiac Disease: Are They Mediated by Brain Perfusion Changes?
  254. Tolerance to baclofen?s sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence
  255. Psychological support counselling improves gluten-free diet compliance in coeliac patients with affective disorders
  256. Gluten-related cerebral hypoperfusion and neurologic disorders in coeliac patients
  257. Suppression of Alcohol Delirium Tremens by Baclofen Administration: A Case Report
  258. Rapid Regression of Psoriasis in a Coeliac Patient after Gluten-Free Diet
  259. Baclofen: clinical data